Analysts Set Expectations for ATNM Q3 Earnings

Actinium Pharmaceuticals, Inc. (NYSE:ATNM) – Investment analysts at Zacks Research issued their Q3 2026 earnings estimates for shares of Actinium Pharmaceuticals in a research report issued to clients and investors on Tuesday, September 15th. Zacks Research analyst J. Vandermosten expects that the company will post earnings of ($0.22) per share for the quarter. The consensus estimate for Actinium Pharmaceuticals’ current full-year earnings is ($1.41) per share. Zacks Research also issued estimates for Actinium Pharmaceuticals’ Q4 2026 earnings at ($0.24) EPS, FY2026 earnings at $0.25 EPS, FY2027 earnings at ($0.65) EPS and FY2028 earnings at ($0.62) EPS.

Actinium Pharmaceuticals Trading Down 0.8%

Actinium Pharmaceuticals stock opened at $1.24 on Thursday. Actinium Pharmaceuticals has a 12-month low of $0.74 and a 12-month high of $1.74. The stock has a market cap of $38.99 million, a P/E ratio of -0.89 and a beta of 0.05. The company has a 50-day moving average price of $0.98 and a 200 day moving average price of $1.08.

Institutional Trading of Actinium Pharmaceuticals

Several hedge funds have recently made changes to their positions in ATNM. Compass Financial Management LLC purchased a new stake in shares of Actinium Pharmaceuticals during the 2nd quarter valued at approximately $588,000. BlackRock Inc. acquired a new position in shares of Actinium Pharmaceuticals in the 2nd quarter worth approximately $388,000. Finally, Renaissance Technologies LLC boosted its position in shares of Actinium Pharmaceuticals by 20.7% during the 1st quarter. Renaissance Technologies LLC now owns 471,600 shares of the company’s stock worth $469,000 after purchasing an additional 80,816 shares during the period. Hedge funds and other institutional investors own 27.50% of the company’s stock.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc is a clinical-stage biotechnology company focused on the development of targeted radiopharmaceutical therapies for patients with hematologic malignancies. The company’s proprietary technology platform combines monoclonal antibodies with radioisotopes to deliver highly potent, cell?killing radiation directly to cancer cells while sparing healthy tissues. Actinium’s lead product candidate, Iomab?B, is being evaluated as a conditioning regimen for older patients with acute myeloid leukemia (AML) who are ineligible for standard bone marrow transplants.

In addition to Iomab?B, Actinium’s pipeline includes Actimab?A, an anti?CD33 antibody labeled with the radioisotope bismuth?213 for the treatment of relapsed or refractory AML.